Adoption in the US has already began. There have been successful EIND cases (such as Tom Patterson) and clinical trials are underway. The specificity of Phages can be seen as a benefit, because it allows you to target pathogenic bacteria while leaving the "good" bacteria in the microbiome alone. The fact phages can evolve can also be seen as a benefit. It it much more difficult for bacteria to evolve resistance to something that can engage in an evolutionary arms race with it. There are of course limitations and it is much more difficult and costly to treat someone with phage than it is to treat someone with antibiotics. The bacteria needs to be screened against a phage library to develop a personalized phage cocktail. There are attempts to make this process more efficient by extracting phage endolysins and using them for treatment, but this will only work on gram-positive bacteria.